A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR
European Journal of Pain2017Vol. 21(9), pp. 1528–1537
Citations Over TimeTop 10% of 2017 papers
Denis Dupoiron, Andrzej Stachowiak, O. Loewenstein, Adam Ellery, Walter K. Kremers, B. Bosse, Michael Hopp
Abstract
Effective analgesia can be achieved using oxycodone/naloxone PR up to 160/80 mg daily without compromising bowel function. A similar outcome was reported in cancer and non-cancer patients.
Related Papers
- → A multinational survey of prevalence and patterns of laxative use among adults with self‐defined constipation(2008)271 cited
- → Constipation in Long-Term Care(2007)88 cited
- → A longitudinal study of constipation and laxative use in a community-dwelling elderly population(2015)37 cited
- → Assessment of Constipation Management in Long-Term Care Patients(2001)46 cited
- → Constipation prophylaxis reduces length of stay in elderly hospitalized heart failure patients with home laxative use(2015)12 cited